Spiral Therapeutics, a South San Francisco, CA-based clinical-stage firm centered on delivering therapies for inside ear problems, raised $8.25M in funding.
The spherical was led by Savoir Capital and Catalio Capital Management with participation from Humboldt Fund, Savoir Capital and Catalio Capital Management.
The firm intends to make use of the funds for the persevering with improvement of its lead candidate, SPT-2101, for the therapy of inside ear irritation.
Led by Hugo Peris, Founder and CEO, Spiral Therapeutics is a clinical-stage firm centered on delivering therapies for inside ear problems. Its novel drug supply platform permits for minimally invasive, exact and sturdy publicity of medicine to the cochlea. The firm is advancing a therapeutic pipeline with concentrate on listening to loss and stability problems. Its lead program, SPT-2101, is a sustained-release steroid formulation for the therapy of inside ear irritation.